Neural Progenitor Cell Sparing Radiation Therapy Plus Temozolomide

NACompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

December 27, 2011

Primary Completion Date

April 25, 2018

Study Completion Date

April 25, 2018

Conditions
Glioblastoma Multiforme
Interventions
RADIATION

Radiation

Patients will be treated to a total dose of 60 Gy with a once daily fractionation schedule of 2 Gy per fraction, administered five days per week. All patients will undergo CT simulation with intravenous contrast. In addition they will undergo MRI simulation with both T1 with gadolinium as well as FLAIR sequences. They will be treated in a supine position using an aquaplast mask system for immobilization. CT image data will be reconstructed in approximately 3 mm slice thickness and manually coregistered with T1 post-gadolinium and FLAIR sequence MRI.

DRUG

Chemotherapy

Temozolomide

Trial Locations (1)

21231

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

All Listed Sponsors
lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT01478854 - Neural Progenitor Cell Sparing Radiation Therapy Plus Temozolomide | Biotech Hunter | Biotech Hunter